Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: Judy who wrote (7105)	9/10/1998 1:06:00 PM
From: XOsDaWAY2GO	Read Replies (2) \| Respond to of 34811

Hi, Judy, Why 57 on IMNX? Barbara

To: Judy who wrote (7105)	9/10/1998 1:12:00 PM
From: Jerry Olson	Respond to of 34811

Sweets.....me? wave my hands???? you gotta be kiddin"..:>} here's the article, it popped the stock at 54ish today... don't know about it holding 57 today the markets tanking as I type...!!!!!!!!! i'm holding and will ADD to my position.... Thursday September 10, 11:13 am Eastern Time Immunex reports positive Novantrone trial results LOS ANGELES, Sept 10 (Reuters) - Drug company Immunex Corp. said Thursday that preliminary results of a phase III clinical trial showed that its Novantrone drug delayed relapses in multiple sclerosis patients. The Seattle-based company already markets Novantrone, known generically as Mitoxantrone, for the treatment of leukemia and prostate cancer but is hoping to gain approval to market the drug for multiple sclerosis. The phase III trial of 194 patients showed the median time to the first relapse was 24 months for those taking the drug compared to 15 months in the placebo group. The trial revealed the annual relapse rate for those on Novantrone was 21 percent or 36 percent, depending on dosage, compared to 60 percent in the placebo group. Multiple sclerosis is a debilitating and potentially paralyzing illness that attacks the nervous system and affects more than 300,000 Americans and more than one million globally. Patients in the trial were given the drug intravenously every three months for two years. Tests run on a sub-group of 100 patients after one and two years revealed no additional scar tissue -- an indication of progression of the illness -- while those in the placebo group showed increased scar tissue. The company also said those patients taking the drug showed a modest increase in neurological function compared to a modest deterioration in those not taking the drug. The mobility of patients taking the drug in the trial deteriorated at a slower pace than in those in the placebo group. ''We are encouraged by the results with Novantrone reported in this study,'' Immunex's Peggy Phillips said. ''We are looking forward to meeting with the Food and Drug Administration to discuss applying for an expanded label for the use of Novantrone in multiple sclerosis.'' Immunex plans to meet regulators in the fall. A spokeswoman for the company said it hoped to secure approval for the drug by the end of 1999 if all goes according to plan. If approved for use by multiple sclerosis patients, Novantrone will compete with Biogen Inc.'s Avonex, Teva Marion Partners' drug Copaxone and Chiron Corp.'s Betaseron. The study, presented at the Congress of the European Committee for the Treatment and Research in Multiple Sclerosis in Stockholm, showed some side affects including reduced white blood cell counts, infection and hair loss. Novantrone is marketed in North America by Immunex and elsewhere by American Home Products' Wyeth-Ayerst International. More Quotes and News: American Home Products Corp (NYSE:AHP - news) Biogen Inc (Nasdaq:BGEN - news) Chiron Corp (Nasdaq:CHIR - news) Immunex Corp (Nasdaq:IMNX - news) Related News Categories: health, US Market News Help Copyright c 1998 Reuters Limited. All rights reserved. Republiaction or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information.